<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82428">
  <stage>Registered</stage>
  <submitdate>13/02/2008</submitdate>
  <approvaldate>20/02/2008</approvaldate>
  <actrnumber>ACTRN12608000097347</actrnumber>
  <trial_identification>
    <studytitle>A double blind, randomised, placebo controlled, multi centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.</studytitle>
    <scientifictitle>placebo controlled adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E2090-E044-317</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epilepsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>adjunctive therapy- Zonisamide. Patients will take study drug (either Zonisamide or Placebo) alongside their usual Antiepileptic drugs. Patients will commence on a dose of 50mg. Further dose increases will occur at one week intervals until a dose of 300mg is reached by week 4. Patients will then maintain their dose for a further 12 weeks.</interventions>
    <comparator>Placebo will be the comparator to Zonisamide. Placebo will be dispensed in the same way as Zonisamide.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>decrease of seizure frequency</outcome>
      <timepoint>a seizure diary will be used to collect information on frequency of Seizures. A diary will be collected from 8 weeks prior to the study until after 16 weeks of active therpay.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>safety -  blood samples will be taken and assessed for safty Laboratory values.</outcome>
      <timepoint>At screening and final visit (after 16 weeks of active therapy)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>myoclonic seizures</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>other type of seizures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sunjects will be enrolled and allocated to a treatment using a central randomisation system by phone.</concealment>
    <sequence>Subjects will be randomised tusing a central randomisation system which will determine the sequence of patients.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3050</postcode>
    <postcode>3084</postcode>
    <postcode>2031</postcode>
    <postcode>2067</postcode>
    <postcode>3065</postcode>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia and Montenegro</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eisai Ltd.</primarysponsorname>
    <primarysponsoraddress>3 Shortlands
London
W6 8EE
UK</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eisai Ltd</fundingname>
      <fundingaddress>3 Shortlands
London
W6 8EE</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Parexel Int.</sponsorname>
      <sponsoraddress>3 Thomas Holt Drive
North Ryde, NSW
2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Parexel International</sponsorname>
      <sponsoraddress>101-105 Oxford Rd. 
The Quays
Uxbrudge, Middlesex,
UB8 1LZ</sponsoraddress>
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to compare how safe and effective zonisamide is compared to placebo in people with myoclonic seizures associated with idiopathic generalised epilepsy who are already being treated with one or two other anti-epileptic drugs. Zonisamide is an investigational drug.
RESEARCH OBJECTIVES
To assess the efficacy of adjunctive zonisamide in idiopathic generalised epilepsy (IGE) in reducing the frequency of myoclonic seizures in subjects with continuing seizures despite treatment with 1 or 2 other anti epileptic drugs (AEDs). To assess the safety and tolerability of zonisamide and explore further efficacy in other seizure types.

STUDY DESIGN
This is a double blind, randomised, placebo controlled study comparing zonisamide and placebo in 110 subjects (1:1ratio). The study consists fo Baseline, Titration and Maintenance periods.

Baseline Period once the Screening Visit has been performed, a seizure diary will be maintained to document the baseline seizure frequency in the eight weeks before the Randomisation Visit. Titration Period zonisamide/placebo dose will commence at at 50 mg. Further dose increases will occur at one week intervals until at dose of 300 mg is reached by Week 4. If adverse events (AEs) occur, one titration step will be omitted during Weeks 0 3, in which case the dose reached at Week 4 will be 250 mg. Subjects who require further down titration during this period will be withdrawn.

Maintenance Period subjects will be treated with their Week 4 dose. In the event of seizures occurring in the first two weeks of the Maintenance Period, the dose will be increased to 400 mg (or 350 mg, if the subject omitted one dose in the Titration Period and the AE that led to this dose increase omission has subsided). The dose can be reduced to 200 mg in the case of dose-limiting AEs. Subjects who require further down titration or dose increases will be withdrawn (with the exception of those who had temporary dose decreases for not more that 4 days when necessitated by intercurrent illness). During the remainder of the Maintenance Period, the dose of study medication must remain unchanged.

During the entire study the patient will keep a seizure diary to ascertain seizure frequency and type. Adverse events (AEs) will be reviewed at every visit, also physical and neurological exams and orthostatic vitals will be collected at every visit.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Ward 6 East, Research Directorate
Gratten St
Parkville
VIC 3050</ethicaddress>
      <ethicapprovaldate>20/02/2008</ethicapprovaldate>
      <hrec>2007.288</hrec>
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Human Research Ethics Commitee</ethicname>
      <ethicaddress>Research Office, RNSH
Level 4
Vindin House,
Pacific Highway, St Leonards
NSW 2065</ethicaddress>
      <ethicapprovaldate>9/07/2008</ethicapprovaldate>
      <hrec>08/HARBA/3/4</hrec>
      <ethicsubmitdate>10/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Commitee</ethicname>
      <ethicaddress>Research Ethics Unit (REU)
Level 8, Room 8322
Harold Stokes Building
Austin Hospital
145 Studley Road
Heidelberg
Victoria
3084</ethicaddress>
      <ethicapprovaldate>4/06/2008</ethicapprovaldate>
      <hrec>H2008/03172</hrec>
      <ethicsubmitdate>16/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital (melbourne) Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 5, Aikenhead Building
27 Victoria Parade
Fitzroy 
VIC 3065</ethicaddress>
      <ethicapprovaldate />
      <hrec>015/08</hrec>
      <ethicsubmitdate>31/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janos Antal</name>
      <address>Hermina utca 17, Budapest, 1146 Hungary</address>
      <phone>36 1 461 7600</phone>
      <fax />
      <email>janos.antal@parexel.com</email>
      <country>Hungary</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sophie Nzongani-Morin</name>
      <address>PAREXEL International
190 Rue Championnet
PARIS, 75018</address>
      <phone>+33 1 44 90-32 31</phone>
      <fax />
      <email>Sophie.Nzongani-Morin@parexel.com</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sophie Nzongani-Morin</name>
      <address>PAREXEL International
190 Rue Championnet
PARIS, 75018</address>
      <phone>+33 1 44 90-32 31</phone>
      <fax />
      <email>Sophie.Nzongani-Morin@parexel.com</email>
      <country>France</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>